Awni WM[au] - Search Results

Year	Number of Results
1985	2
1986	1
1987	7
1988	8
1989	5
1990	7
1991	9
1992	3
1993	1
1994	3
1995	16
1996	1
1997	3
1998	5
2005	1
2008	1
2009	1
2010	1
2011	3
2012	3
2013	2
2014	2
2015	6
2016	11
2017	8
2018	3
2022	0

1

Clinical Pharmacokinetics of Paritaprevir.

Menon RM, Polepally AR, Khatri A, Awni WM, Dutta S. Menon RM, et al. Among authors: awni wm. Clin Pharmacokinet. 2017 Oct;56(10):1125-1137. doi: 10.1007/s40262-017-0520-x. Clin Pharmacokinet. 2017. PMID: 28236252 Review.

2

Industry Perspective on Standardizing Food-Effect Studies for New Drug Development.

Marroum PJ, Nuthalapati S, Parikh A, Shebley M, Hoffman D, Zha J, Khatri A, Awni WM. Marroum PJ, et al. Among authors: awni wm. Clin Pharmacokinet. 2018 Aug;57(8):901-909. doi: 10.1007/s40262-018-0630-0. Clin Pharmacokinet. 2018. PMID: 29460023 Review.

3

Pharmacodynamic monitoring of cyclosporin.

Awni WM. Awni WM. Clin Pharmacokinet. 1992 Dec;23(6):428-48. doi: 10.2165/00003088-199223060-00004. Clin Pharmacokinet. 1992. PMID: 1458762 Review.

4

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.

King JR, Dutta S, Cohen D, Podsadecki TJ, Ding B, Awni WM, Menon RM. King JR, et al. Among authors: awni wm. Antimicrob Agents Chemother. 2015 Nov 23;60(2):855-61. doi: 10.1128/AAC.01913-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26596948 Free PMC article. Clinical Trial.

5

Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

St Peter JV, Awni WM. St Peter JV, et al. Among authors: awni wm. Clin Pharmacokinet. 1991 Jan;20(1):50-65. doi: 10.2165/00003088-199120010-00004. Clin Pharmacokinet. 1991. PMID: 2029802 Review.

6

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.

Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM. Badri PS, et al. Among authors: awni wm. Antimicrob Agents Chemother. 2015 Oct 12;60(1):105-14. doi: 10.1128/AAC.01778-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26459906 Free PMC article. Clinical Trial.

7

Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.

Lin CW, Mostafa NM, L Andress D, J Brennan J, Klein CE, Awni WM. Lin CW, et al. Among authors: awni wm. Clin Ther. 2018 Feb;40(2):242-251. doi: 10.1016/j.clinthera.2017.07.011. Epub 2017 Jul 27. Clin Ther. 2018. PMID: 28756065

8

Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.

Goss SL, Klein CE, Jin Z, Locke CS, Rodila RC, Kupper H, Burmester GR, Awni WM. Goss SL, et al. Among authors: awni wm. Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002. Clin Ther. 2018. PMID: 29402521 Clinical Trial.

9

Effect of zileuton on theophylline pharmacokinetics.

Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dubé LM, Awni WM. Granneman GR, et al. Among authors: awni wm. Clin Pharmacokinet. 1995;29 Suppl 2:77-83. doi: 10.2165/00003088-199500292-00011. Clin Pharmacokinet. 1995. PMID: 8620674 Clinical Trial.

10

Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.

Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Polepally AR, et al. Among authors: awni wm. Clin Pharmacol Drug Dev. 2016 Jul;5(4):269-77. doi: 10.1002/cpdd.246. Epub 2016 Jan 24. Clin Pharmacol Drug Dev. 2016. PMID: 27310328 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results